Wells Fargo & Company Cuts Teleflex (NYSE:TFX) Price Target to $114.00

Teleflex (NYSE:TFX) had its price target dropped by stock analysts at Wells Fargo & Company from $131.00 to $114.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the medical technology company’s stock. Wells Fargo & Company‘s price target suggests a potential upside of 4.22% from the company’s current price.

Other equities research analysts have also issued reports about the stock. Royal Bank Of Canada decreased their price target on shares of Teleflex from $135.00 to $120.00 and set a “sector perform” rating on the stock in a report on Friday. Weiss Ratings restated a “sell (d+)” rating on shares of Teleflex in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Teleflex from a “strong-buy” rating to a “buy” rating in a report on Monday, September 15th. Mizuho increased their price target on Teleflex from $130.00 to $135.00 and gave the company a “neutral” rating in a research note on Friday, August 1st. Finally, Zacks Research lowered Teleflex from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 30th. One analyst has rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $137.00.

Teleflex Price Performance

Shares of TFX traded up $0.88 during midday trading on Friday, hitting $109.39. The company’s stock had a trading volume of 895,574 shares, compared to its average volume of 743,730. The company has a quick ratio of 1.44, a current ratio of 2.41 and a debt-to-equity ratio of 0.42. Teleflex has a one year low of $102.58 and a one year high of $200.15. The stock has a market capitalization of $4.83 billion, a price-to-earnings ratio of 25.74, a price-to-earnings-growth ratio of 1.79 and a beta of 1.05. The company’s fifty day simple moving average is $126.01 and its two-hundred day simple moving average is $123.27.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, November 6th. The medical technology company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.38 by $0.29. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The business had revenue of $892.90 million during the quarter, compared to the consensus estimate of $892.79 million. During the same period in the prior year, the company earned $3.49 EPS. Teleflex’s revenue for the quarter was up 19.4% on a year-over-year basis. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS. As a group, equities analysts expect that Teleflex will post 13.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Teleflex

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Teacher Retirement System of Texas acquired a new position in shares of Teleflex in the first quarter worth approximately $1,242,000. Brown Advisory Inc. raised its holdings in Teleflex by 34.2% during the 1st quarter. Brown Advisory Inc. now owns 2,524 shares of the medical technology company’s stock worth $349,000 after purchasing an additional 643 shares during the last quarter. Allworth Financial LP lifted its position in shares of Teleflex by 504.8% in the 1st quarter. Allworth Financial LP now owns 254 shares of the medical technology company’s stock worth $34,000 after purchasing an additional 212 shares during the period. Sage Rhino Capital LLC bought a new stake in shares of Teleflex in the 1st quarter valued at $283,000. Finally, New York State Common Retirement Fund boosted its stake in shares of Teleflex by 5.1% in the 1st quarter. New York State Common Retirement Fund now owns 25,639 shares of the medical technology company’s stock valued at $3,543,000 after purchasing an additional 1,239 shares during the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.